Atossa Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Atossa Therapeutics (ATOS).

Price Target Range — 12 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$21Upside to Avg. PT+791.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$24→$25
Jul 7, 2026	Rodman & Renshaw	Michael G. King Jr.	Initiate	Buy	$12
Apr 10, 2026	Ascendiant Capital	Edward Woo	PT Cut	Buy	$120→$24
Mar 26, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$7→$25
Dec 8, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
Sep 22, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
Jun 6, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$7→$8
Jun 5, 2025	Craig-Hallum	Albert Lowe	Initiate	Buy	$4
Apr 21, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$7→$7
Mar 26, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$7
Mar 12, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$7
Jan 30, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$7
Dec 13, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$7
Dec 12, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	—
Dec 9, 2024	Ascendiant Capital	Edward Woo	PT Raise	Buy	$7→$7
Nov 13, 2024	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$6→$7
Nov 5, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$6
Oct 31, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$6
Sep 11, 2024	Ascendiant Capital	Edward Woo	PT Raise	Buy	$6→$7
Aug 12, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$6

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.

Benzinga Newsdesk

PRO
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and lowers the price target from $120 to $24.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $25.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.75 to $8.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.5 to $7.75.

Benzinga Newsdesk

Atossa Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Atossa Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRO
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

PRO
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75

People Also Watch

People Also Watch

Atossa Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Atossa Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAscendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRORodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

PROAscendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

PROHC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PROAscendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

PROAscendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRO
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

PRO
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75